Chinese insulin breaks into US market as new drug secures FDA approval

Sunshine Lake Pharma has become the first Chinese pharmaceutical company to receive US FDA approval for a long-acting insulin product. Its insulin glargine injection, sold as Langlara, is now the fourth product of its kind approved in the US market, alongside products from Novo Nordisk, Sanofi, and Eli Lilly.

The drug received an interchangeable designation, allowing pharmacists to substitute it for branded versions without a new prescription. Sunshine Lake Pharma has already secured a major supply deal with US partner Lannett.

The approval is seen as a major milestone for China’s biopharmaceutical industry and could help the company expand further into global markets as demand grows for lower-cost insulin alternatives in the US.

Credit : CGTN